Wells Fargo’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.84M | Buy |
130,054
+49,660
| +62% | +$1.03M | ﹤0.01% | 3322 |
|
|
2026
Q1 | $1.88M | Sell |
80,394
-80,456
| -50% | -$1.75M | ﹤0.01% | 3319 |
|
|
2025
Q4 | $3.38M | Buy |
160,850
+103,934
| +183% | +$1.81M | ﹤0.01% | 3019 |
|
|
2025
Q3 | $876K | Sell |
56,916
-97,490
| -63% | -$1.28M | ﹤0.01% | 3904 |
|
|
2025
Q2 | $1.45M | Buy |
154,406
+111,446
| +259% | +$1.23M | ﹤0.01% | 3464 |
|
|
2025
Q1 | $528K | Buy |
42,960
+843
| +2% | +$11.9K | ﹤0.01% | 4053 |
|
|
2024
Q4 | $557K | Buy |
42,117
+11,498
| +38% | +$197K | ﹤0.01% | 4100 |
|
|
2024
Q3 | $589K | Sell |
30,619
-550
| -2% | -$11.4K | ﹤0.01% | 3885 |
|
|
2024
Q2 | $640K | Buy |
31,169
+1,996
| +7% | +$41.8K | ﹤0.01% | 3757 |
|
|
2024
Q1 | $694K | Buy |
29,173
+6,280
| +27% | +$140K | ﹤0.01% | 3673 |
|
|
2023
Q4 | $495K | Sell |
22,893
-46,777
| -67% | -$719K | ﹤0.01% | 3879 |
|
|
2023
Q3 | $1.01M | Sell |
69,670
-19,227
| -22% | -$364K | ﹤0.01% | 3320 |
|
|
2023
Q2 | $1.86M | Buy |
88,897
+25,973
| +41% | +$541K | ﹤0.01% | 2972 |
|
|
2023
Q1 | $1.33M | Buy |
62,924
+57,849
| +1,140% | +$1.44M | ﹤0.01% | 3172 |
|
|
2022
Q4 | $129K | Sell |
5,075
-1,997
| -28% | -$46.6K | ﹤0.01% | 4412 |
|
|
2022
Q3 | $170K | Buy |
7,072
+677
| +11% | +$15.2K | ﹤0.01% | 4332 |
|
|
2022
Q2 | $122K | Sell |
6,395
-4,999
| -44% | -$83.3K | ﹤0.01% | 4535 |
|
|
2022
Q1 | $198K | Sell |
11,394
-14,768
| -56% | -$249K | ﹤0.01% | 4988 |
|
|
2021
Q4 | $572K | Buy |
26,162
+20,711
| +380% | +$383K | ﹤0.01% | 4555 |
|
|
2021
Q3 | $104K | Hold |
5,451
| – | – | ﹤0.01% | 5376 |
|
|
2021
Q2 | $94K | Sell |
5,451
-4,404
| -45% | -$80.7K | ﹤0.01% | 5321 |
|
|
2021
Q1 | $219K | Sell |
9,855
-52,250
| -84% | -$1.18M | ﹤0.01% | 5104 |
|
|
2020
Q4 | $1.38M | Sell |
62,105
-670
| -1% | -$13.9K | ﹤0.01% | 3775 |
|
|
2020
Q3 | $926K | Sell |
62,775
-24,510
| -28% | -$374K | ﹤0.01% | 3920 |
|
|
2020
Q2 | $1.29M | Buy |
87,285
+62,660
| +254% | +$954K | ﹤0.01% | 3610 |
|
|
2020
Q1 | $270K | Sell |
24,625
-35,655
| -59% | -$335K | ﹤0.01% | 4483 |
|
|
2019
Q4 | $530K | Buy |
60,280
+32,568
| +118% | +$239K | ﹤0.01% | 4318 |
|
|
2019
Q3 | $206K | Sell |
27,712
-11,525
| -29% | -$105K | ﹤0.01% | 4941 |
|
|
2019
Q2 | $365K | Sell |
39,237
-8,535
| -18% | -$62.2K | ﹤0.01% | 4600 |
|
|
2019
Q1 | $251K | Buy |
47,772
+4,783
| +11% | +$27.3K | ﹤0.01% | 4705 |
|
|
2018
Q4 | $192K | Buy |
42,989
+27,477
| +177% | +$151K | ﹤0.01% | 4935 |
|
|
2018
Q3 | $125K | Buy |
15,512
+4,756
| +44% | +$33.9K | ﹤0.01% | 5254 |
|
|
2018
Q2 | $76K | Buy |
10,756
+456
| +4% | +$4.47K | ﹤0.01% | 5480 |
|
|
2018
Q1 | $146K | Buy |
10,300
+1,039
| +11% | +$11K | ﹤0.01% | 5141 |
|
|
2017
Q4 | $81K | Buy |
9,261
+2,224
| +32% | +$22K | ﹤0.01% | 5385 |
|
|
2017
Q3 | $83K | Buy |
7,037
+5,389
| +327% | +$66.1K | ﹤0.01% | 5304 |
|
|
2017
Q2 | $23K | Hold |
1,648
| – | – | ﹤0.01% | 5602 |
|
|
2017
Q1 | $23K | Hold |
1,648
| – | – | ﹤0.01% | 5680 |
|
|
2016
Q4 | $12K | Hold |
1,648
| – | – | ﹤0.01% | 5753 |
|
|
2016
Q3 | $25K | Buy |
+1,648
| New | +$21.7K | ﹤0.01% | 5540 |
|
Other funds holding SNDX
KCM
DM
EP
HRCM
Wells Fargo's SNDX Position: Q2 2026 in Review
Wells Fargo increased its Syndax Pharmaceuticals (SNDX) stake by 62% in Q2 2026, buying an estimated $1.03M and bringing the position to 130,054 shares worth $2.84M. The position accounts for ﹤0.01% of the portfolio, ranked #3322.
Wells Fargo first reported a position in SNDX in Q3 2016 and has held it in 40 quarters since. The position peaked at $3.38M in Q4 2025. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.
- Wells Fargo held 130,054 shares of Syndax Pharmaceuticals worth $2.84M as of Q2 2026.
- Wells Fargo bought 49,660 Syndax Pharmaceuticals shares in Q2 2026, an estimated $1.03M.
- Syndax Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3322 holding.
- Wells Fargo first reported a position in Syndax Pharmaceuticals in Q3 2016 and has held it in 40 quarters since.
- Wells Fargo's Syndax Pharmaceuticals position peaked at $3.38M in Q4 2025.
- 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.